Close Menu

NEW YORK – Bio-Path Holdings has dosed the first patient in its Phase I clinical trial evaluating BP1002, a BCL-2 inhibitor, as a treatment for refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) patients.

The trial has enrolled six patients to evaluate BP1002 as a monotherapy. The primary endpoints are determining the safety and tolerability of escalating doses of BP1002, the recommended Phase 2 dose of BP1002, pharmacokinetics of BP1002, and BP1002 activity on BCL-2 expression. Secondary endpoints are measurements of tumor response.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.